Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.12, Bloomberg Earnings reports.

Shares of Aclaris Therapeutics (ACRS) opened at 26.97 on Thursday. The stock’s market capitalization is $720.99 million. The company has a 50-day moving average of $27.89 and a 200 day moving average of $27.99. Aclaris Therapeutics has a 12-month low of $18.24 and a 12-month high of $33.25.

COPYRIGHT VIOLATION NOTICE: “Aclaris Therapeutics, Inc. (ACRS) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/10/aclaris-therapeutics-inc-acrs-posts-quarterly-earnings-results-beats-estimates-by-0-12-eps.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS Group AG increased its position in shares of Aclaris Therapeutics by 60.4% in the first quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock worth $133,000 after buying an additional 1,681 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Aclaris Therapeutics by 269.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,801 shares of the biotechnology company’s stock worth $143,000 after buying an additional 3,500 shares during the last quarter. Legal & General Group Plc increased its position in shares of Aclaris Therapeutics by 98.3% in the second quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock worth $142,000 after buying an additional 2,605 shares during the last quarter. First Mercantile Trust Co. increased its position in shares of Aclaris Therapeutics by 11.2% in the first quarter. First Mercantile Trust Co. now owns 5,945 shares of the biotechnology company’s stock worth $177,000 after buying an additional 600 shares during the last quarter. Finally, Nationwide Fund Advisors increased its position in shares of Aclaris Therapeutics by 8.3% in the first quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock worth $198,000 after buying an additional 510 shares during the last quarter. 88.64% of the stock is owned by institutional investors.

Several equities analysts have recently weighed in on the stock. Jefferies Group LLC set a $36.00 price objective on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 20th. BidaskClub raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, July 24th. Guggenheim reissued a “buy” rating and issued a $40.00 target price on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a report on Wednesday. Finally, Zacks Investment Research lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 12th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $39.00.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.